🩺 Expert Opinion by Dr. Chetan R. Kalal
Maharashtra’s First DM Hepatologist | India’s Leading Liver & Transplant Specialist | Global Virtual Consults
⚕️ Hepatology Update
Liver diseases are rising at an alarming pace across India and globally. Fatty liver (MASLD), viral hepatitis, and alcohol-related liver disease remain the top drivers of cirrhosis. Early diagnosis with non-invasive tests (FibroScan, MRI-PDFF, advanced blood biomarkers) now helps detect scarring before symptoms appear.
Dr. Kalal’s perspective:
"In 2025, the biggest shift in hepatology is moving from late-stage rescue to early-stage prevention. Patients must understand that fatty liver today is cirrhosis tomorrow if ignored. Regular liver check-ups are no longer optional — they are essential."
🏥 Liver Transplant & IPD Services
India is now a hub for world-class liver transplantation, with outcomes comparable to the best global centers. But transplant is just the tip of the iceberg.
Dr. Kalal emphasizes IPD (In-Patient Department) services as the backbone of liver care:
Acute Liver Failure management with ICU-level monitoring
Cirrhosis complications – ascites, variceal bleeding, encephalopathy
Bridging therapies – plasma exchange, nutrition, infection control
Pre- & Post-Transplant Care – infection prevention, immunosuppression optimization
"A liver transplant is never just a surgery. It is a journey — starting with IPD stabilization, multidisciplinary teamwork, and lifelong follow-up. My mission is to ensure patients and families feel supported every step of the way."
⚖️ Obesity & Liver Disease Updates
Obesity is now the single largest risk factor for fatty liver, diabetes, and liver cancer. In India, 1 in 3 urban adults are overweight, and the liver is the silent victim.
New pharmacological breakthroughs are transforming treatment:
GLP-1 agonists (Semaglutide, Tirzepatide): not just weight loss drugs, but powerful tools against fatty liver and metabolic syndrome.
Resmetirom (Rezdiffra): the first FDA-approved therapy for NASH, a game-changer in preventing progression to cirrhosis.
"Obesity is not just about body image. It is a liver disease in disguise. For many patients, weight loss of 7–10% can reverse fatty liver. With modern drugs and a structured clinic model, we can finally treat obesity as a medical condition, not a lifestyle failure."
🌍 Global & Virtual Reach
Patients from USA, UAE, Europe, Canada, Australia, New Zealand, Africa, and across India consult Dr. Kalal virtually for:
Second opinions on transplant
Complex hepatology cases
Obesity and fatty liver management
"Whether you are in Mumbai or Melbourne, my aim is the same — evidence-based, compassionate care tailored to your needs."
❓ FAQs
Q: Is a liver transplant safe in India?
Yes. With expert teams and advanced facilities, India’s transplant outcomes are globally competitive, at a fraction of the cost.
Q: Does obesity always lead to fatty liver?
Not always, but obesity greatly increases the risk. Up to 70% of obese individuals have fatty liver on imaging.
Q: Can fatty liver be reversed?
Yes — with weight loss, medicines like GLP-1 agonists, and early intervention. The earlier it’s detected, the higher the chance of reversal.
Q: How do I book IPD or a virtual consultation with Dr. Kalal?
Patients can be admitted under Dr. Kalal’s IPD care in Mumbai, or book structured virtual consults worldwide.
📢 Conclusion
Hepatology is rapidly evolving — from AI-driven diagnostics to new obesity drugs and cutting-edge transplant care. But one truth remains: early action saves livers.
👉 Dr. Chetan Kalal combines clinical expertise, global vision, and compassionate care to lead this new era of liver health.
